Spiderwort Biotechnologies Inc.
Spiderwort Biotechnologies Inc. is pioneering regenerative medicine through the development of innovative plant-based biomaterials. The company focuses on creating scaffolds for tissue repair and regeneration, with promising applications in spinal cord injuries and soft tissue regeneration. Inspired by the work of TED Fellow Andrew E. Pelling and spun out from the University of Ottawa, Spiderwort is committed to transforming biotechnology and advancing medical aesthetics and regenerative medicine.
Industries
Nr. of Employees
small (1-50)
Spiderwort Biotechnologies Inc.
7 Bayview Station Road, Ottawa, Ontario, K1Y 2C5
Products
CelluBridge
An implantable cellulose-derived scaffold under development designed to support repair and regeneration of spinal cord tissue by guiding regenerating neurons through microchannel architecture.
CelluJuve
A cellulose-derived injectable dermal filler under development intended to provide structural support for soft tissue augmentation and facial tissue rejuvenation.
CelluBridge
An implantable cellulose-derived scaffold under development designed to support repair and regeneration of spinal cord tissue by guiding regenerating neurons through microchannel architecture.
CelluJuve
A cellulose-derived injectable dermal filler under development intended to provide structural support for soft tissue augmentation and facial tissue rejuvenation.
Expertise Areas
- Cellulose-based biomaterials
- Tissue engineering and scaffold design
- Spinal cord injury therapies and neuroregeneration
- Dermal filler formulation and medical aesthetics
Key Technologies
- Cellulose-based scaffold fabrication
- Microchannel scaffold architecture
- Injectable biomaterial formulations
- ISO 10993 biocompatibility testing
News & Updates
Spiderwort announced it has received Investigational Testing Authorization from Health Canada for CelluJuve®, a next-generation cellulose-based dermal filler.
The company announced the completion of ISO 10993 biocompatibility testing and human skin safety testing for CelluJuve®, supporting its advancement towards clinical trials.
The company announced the construction of a new ISO 5 cleanroom facility to support the development and manufacturing of its biomaterials.
Recognition for the innovative work with CelluJuve technology, suggesting improvements in dermal filler durability.
Award recognizing the company's contributions to the industry.
Joining a prestigious innovation hub in Toronto to accelerate development and clinical trials.
Spiderwort announced it has received Investigational Testing Authorization from Health Canada for CelluJuve®, a next-generation cellulose-based dermal filler.
The company announced the completion of ISO 10993 biocompatibility testing and human skin safety testing for CelluJuve®, supporting its advancement towards clinical trials.
The company announced the construction of a new ISO 5 cleanroom facility to support the development and manufacturing of its biomaterials.
Recognition for the innovative work with CelluJuve technology, suggesting improvements in dermal filler durability.
Award recognizing the company's contributions to the industry.
Joining a prestigious innovation hub in Toronto to accelerate development and clinical trials.